Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.04 EUR
Change Today 0.00 / 0.00%
Volume 5.0K
As of 3:35 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

agennix ag (AGX) Snapshot

Open
€0.05
Previous Close
€0.04
Day High
€0.07
Day Low
€0.04
52 Week High
08/12/15 - €0.15
52 Week Low
01/14/15 - €0.0090
Market Cap
2.3M
Average Volume 10 Days
10.6K
EPS TTM
€-2.54
Shares Outstanding
51.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGENNIX AG (AGX)

Related News

No related news articles were found.

agennix ag (AGX) Related Businessweek News

No Related Businessweek News Found

agennix ag (AGX) Details

Agennix AG operates as a biopharmaceutical company in Princeton, New Jersey. It focuses on developing novel therapies that have the potential to lengthen and enhance the lives of critically ill patients in areas of unmet medical need. The company’s lead product candidate under development is Talactoferrin, an oral dendritic cell that establishes and functions body’s immune system, which has completed Phase III trial enrollment for the treatment of non-small cell lung cancer; and Phase II clinical trial for the treatment of severe sepsis. Its developmental stage products include topical talactoferrin, which has completed Phase IIa clinical trial for the treatment of diabetic foot ulcers; satraplatin, an oral platinum gel that has completed Phase I trial for oncology; and RGB-286638, a multi-targeted kinase inhibitor that has completed Phase I trial for the treatment of solid tumors. The company is based in Heidelberg, Germany.

52 Employees
Last Reported Date: 11/30/12

agennix ag (AGX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGX:GR €0.04 EUR 0.00

AGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGX.
View Industry Companies
 

Industry Analysis

AGX

Industry Average

Valuation AGX Industry Range
No financial data is available for AGX.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENNIX AG, please visit www.agennix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.